Literature DB >> 6381191

Hyperinsulinaemia in non-cirrhotic haemochromatosis: impaired hepatic insulin degradation?

C Niederau, M Berger, W Stremmel, A Starke, G Strohmeyer, R Ebert, E Siegel, W Creutzfeldt.   

Abstract

This study investigated early alterations of glucose metabolism in idiopathic haemochromatosis. Circulating concentrations of glucose, insulin, C-peptide, glucagon, and gastric inhibitory polypeptide (GIP) were measured after a 100-g oral glucose load in 10 men with idiopathic haemochromatosis in the non-cirrhotic stage of the disease. All had normal glucose tolerance and normal body weight. Ten matched healthy subjects were studied as controls. Insulin concentrations increased to significantly higher levels in patients with idiopathic haemochromatosis than in the control subjects from 30 to 180 min after the glucose load (p less than or equal to 0.01), while fasting insulin concentrations were not significantly different (p greater than 0.05). Concentrations of glucose, glucagon, C-peptide, and GIP were not significantly different at any time (p greater than 0.05). Thus, patients with idiopathic haemochromatosis show hyperinsulinaemia and hence insulin resistance without impaired glucose tolerance in the non-cirrhotic stage. Since pancreatic insulin secretion (C-peptide), glucagon secretion, and the entero-insulinar axis (GIP) are not impaired in these non-cirrhotic patients with idiopathic haemochromatosis, iron accumulation in the hepatocytes may be responsible for the impaired insulin effect and may cause impaired hepatic insulin extraction.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6381191     DOI: 10.1007/bf00262217

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  17 in total

1.  Glucose tolerance and diabetes in chronic liver disease.

Authors:  C Megyesi; E Samols; V Marks
Journal:  Lancet       Date:  1967-11-18       Impact factor: 79.321

2.  Idiopathic haemochromatosis and diabetes mellitus.

Authors:  R Saddi; J Feingold
Journal:  Clin Genet       Date:  1974       Impact factor: 4.438

3.  Iron excess, early glucose intolerance and impaired insulin secretion in idiopathic haemochromatosis.

Authors:  B B de Haan; J R Scherrer; W Stauffacher; D Pometta
Journal:  Eur J Clin Invest       Date:  1973-05       Impact factor: 4.686

4.  Studies on the diabetic syndrome of idiopathic haemochromatosis.

Authors:  G Pozza; A Ghidoni
Journal:  Diabetologia       Date:  1968-03       Impact factor: 10.122

5.  Insulin resistance in humans.

Authors:  J M Olefsky
Journal:  Gastroenterology       Date:  1982-12       Impact factor: 22.682

6.  C-peptide and insulin in liver disease.

Authors:  D G Johnston; G M Alberti; R Wright; G Smith-Laing; A M Stewart; S Sherlock; O Faber; C Binder
Journal:  Diabetes       Date:  1978       Impact factor: 9.461

7.  [Raised plasma glucagon levels in obesity (author's transl)].

Authors:  A Starke; G Starke; V Jörgens; M Berger; H Zimmermann
Journal:  Dtsch Med Wochenschr       Date:  1982-07-23       Impact factor: 0.628

8.  [Diabetes mellitus in idiopathic haemochromatosis (author's transl)].

Authors:  G Strohmeyer; H Gottesbüren; C Behr; H Sauer
Journal:  Dtsch Med Wochenschr       Date:  1976-07-09       Impact factor: 0.628

9.  Plasma glucagon in diabetes of haemochromatosis: too low or too high?

Authors:  W A Muller; M Berger; H J Cüppers; P Berchtold; G Strohmeyer; A E Renold; J R Hofstetter; J J Gonvers
Journal:  Gut       Date:  1979-03       Impact factor: 23.059

10.  Insulin resistance and insulin receptors in hepatic cirrhosis.

Authors:  A T Blei; D C Robbins; E Drobny; G Baumann; A H Rubenstein
Journal:  Gastroenterology       Date:  1982-12       Impact factor: 22.682

View more
  37 in total

1.  Diabetes, cancer and iron.

Authors:  L Mascitelli; F Pezzetta; M R Goldstein
Journal:  Diabetologia       Date:  2010-06-23       Impact factor: 10.122

2.  Iron and glucose homeostasis: new lessons from hereditary haemochromatosis.

Authors:  J G Wilson
Journal:  Diabetologia       Date:  2006-07       Impact factor: 10.122

3.  Serum ferritin-a novel risk factor in acute myocardial infarction.

Authors:  M P Holay; A A Choudhary; S D Suryawanshi
Journal:  Indian Heart J       Date:  2012-04-28

4.  Relationship between free iron and glycated hemoglobin in uncontrolled type 2 diabetes patients associated with complications.

Authors:  Jeevan K Shetty; Mungli Prakash; Mohammad S Ibrahim
Journal:  Indian J Clin Biochem       Date:  2008-03-06

5.  Hyperinsulinism in iron overload.

Authors:  P Dandona; D M Flynn; A V Hoffbrand
Journal:  Diabetologia       Date:  1984-12       Impact factor: 10.122

6.  Associations between red meat intake and biomarkers of inflammation and glucose metabolism in women.

Authors:  Sylvia H Ley; Qi Sun; Walter C Willett; A Heather Eliassen; Kana Wu; An Pan; Fran Grodstein; Frank B Hu
Journal:  Am J Clin Nutr       Date:  2013-11-27       Impact factor: 7.045

7.  Effects of Cardiorespiratory Fitness on Serum Ferritin Concentration and Incidence of Type 2 Diabetes: Evidence from the Aerobics Center Longitudinal Study (ACLS).

Authors:  Tuan D Le; Sejong Bae; Chiehwen Ed Hsu; Karan P Singh; Steven N Blair; Ning Shang
Journal:  Rev Diabet Stud       Date:  2009-02-10

8.  Association of oxidative stress, iron, and centralized fat mass in healthy postmenopausal women.

Authors:  Betsy L Crist; D Lee Alekel; Laura M Ritland; Laura N Hanson; Ulrike Genschel; Manju B Reddy
Journal:  J Womens Health (Larchmt)       Date:  2009-06       Impact factor: 2.681

9.  Association of Serum Ferritin Levels with Metabolic Syndrome in India: a Cross-Sectional Study.

Authors:  Meena Ramesh Chand; Nagina Agarwal; Dev Nishanth; Sankar Jhuma
Journal:  Maedica (Bucur)       Date:  2021-03

10.  Risk Factors for Insulin Resistance, Metabolic Syndrome, and Diabetes in 248 HFE C282Y Homozygotes Identified by Population Screening in the HEIRS Study.

Authors:  James C Barton; J Clayborn Barton; Paul C Adams; Ronald T Acton
Journal:  Metab Syndr Relat Disord       Date:  2016-01-15       Impact factor: 1.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.